Bioventus Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $568.1M | $573.3M | $512.3M | $512.1M | $430.9M |
| Cost of revenue | $179.9M | $185.1M | $184.2M | $181.0M | $128.2M |
| Gross profit | $388.2M | $388.2M | $328.2M | $331.1M | $302.7M |
| Selling, general & administrative | $314.0M | $343.8M | $303.9M | $332.1M | $254.3M |
| Research and development | $12.1M | $14.0M | $13.4M | $23.9M | $19.0M |
| Operating income | $54.0M | -$15.2M | -$81.7M | -$167.2M | $12.1M |
| Pretax income | $25.7M | -$52.3M | -$121.1M | -$189.0M | $9.5M |
| Income tax expense | -$1.6M | -$5.3M | $85,000 | -$44.4M | -$2.0M |
| Net income | $22.7M | -$36.1M | -$156.2M | -$158.7M | $19.4M |
| Balance Sheet | |||||
| Cash and equivalents | $51.2M | $41.6M | $37.0M | $30.2M | $43.9M |
| Current assets | $272.8M | $275.6M | $268.0M | $272.6M | $263.1M |
| Total assets | $683.6M | $728.0M | $810.9M | $1.4B | $1.2B |
| Current liabilities | $160.4M | $210.4M | $175.5M | $304.0M | $180.9M |
| Total liabilities | $455.1M | $542.4M | $589.8M | $960.4M | $618.2M |
| Stockholders' equity | $184.1M | $147.9M | $173.6M | $325.2M | $458.9M |
| Cash Flow Statement | |||||
| Cash from operations | $74.7M | $38.8M | $15.3M | -$13.5M | $23.0M |
| Depreciation and amortization | $47.0M | $49.6M | $57.4M | $55.4M | $34.9M |
| Stock-based compensation | $12.7M | $13.3M | $2.7M | $17.6M | $19.8M |
| Capital expenditure | $2.6M | $1.0M | $7.4M | $1.5M | $13.5M |
| Free cash flow | $72.1M | $37.8M | $8.0M | -$15.0M | $9.5M |
| Impairments | $0 | $36.4M | $78.6M | $135.0M | $7.0M |
Shares outstanding 83.5M · Free float 19.2%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.